Blog
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade
Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
…
11th Feb 2025
Crizanlizumab: A Comprehensive Overview of Its Role in Sickle Cell Disease and Ongoing Research
Quick Facts About CrizanlizumabWhat is Crizanlizumab?Crizanlizumab is a monoclonal antibody used to treat sickle cell disease by targeting P-selectin, a protein involved in inflammation
…
7th Feb 2025
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy
What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
…
6th Feb 2025
Alsevalimab: Targeting CD47 for Cancer Research and Treatment
Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
…
6th Feb 2025
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research
Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
…
5th Feb 2025
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements
Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
…
5th Feb 2025
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research
Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
…
4th Feb 2025
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances
What You Need to Know About DenosumabWhat is Denosumab?Denosumab is a monoclonal antibody used primarily to treat osteoporosis and bone-related complications in cancer patients. It targe
…
2nd Feb 2025
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research
Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
…
29th Jan 2025
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights
Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
…
29th Jan 2025
Enapotamab: Advancing Cancer Research with Innovative Therapeutics
Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
…
29th Jan 2025
Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential
Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm
…
28th Jan 2025
Belimumab: Unveiling Its Role in Lupus and Beyond
Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na
…
28th Jan 2025
Basiliximab: Mechanism, Clinical Applications, and Research Advancements
Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
…
22nd Jan 2025
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy
What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
…
16th Jan 2025
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research
What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
…
15th Jan 2025
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation
What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
…
15th Jan 2025
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research
What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
…
15th Jan 2025
Varlilumab: Unlocking CD27’s Potential in Cancer Research
What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
…
5th Dec 2024